Compare BioNano Genomics Inc (BNGO) vs Gartner Inc (IT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Gartner Inc — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.66M), while Gartner Inc trades at $181.15 (market cap $11.83B). The key difference: Gartner Inc is far larger — about 866× BioNano Genomics Inc's market cap, and Gartner Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | IT | |
|---|---|---|
Market Cap | $13.66M | $11.83B |
Sector | Health | Technology |
52-Week High | $4.92 | $264.09 |
52-Week Low | $1.06 | $125.68 |
Enterprise Value | $16.26M | $13.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
Gartner (IT) trades at $185.09, down 4.18% today, following a strong earnings beat in Q2 2026 with EPS of $4.37 versus $3.76 expected. The stock shows a bullish technical trend but trades above the consensus price target of $172.80. Recent news highlights a shareholder investigation and raised full-year EPS guidance, creating mixed sentiment amid strong profitability metrics like a 69.63% gross margin and 113.58% ROE.
The outlook is cautiously optimistic given earnings momentum and valuation discounts, but risks include consulting segment weakness, negative net cash flow trends, and the fiduciary investigation. Upside depends on sustained execution against guidance, while downside could stem from growth deceleration or legal overhangs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →
